Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zosano Pharma Corporation ZSAN

"Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company operates in one business segment which is developing human pharmaceutical products. All the business activity of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan d

View modes: 

zsan announce RESULTS for qrypta & to file FOR NDA BY FEB 20

Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society September 09, 2019 08:30 ET |...read more

ZOSAN ANNOUNCES IND FILING PHASE 2/3 CLINICAL STUDY

Zosano Pharma (ZSAN) Announces IND Filing to Initiate Phase 2/3 Clinical Study in Cluster Headache August 14, 2019 9:01 AM EDT    Zosano Pharma Corporation (NASDAQ: ZSAN) today...read more

ZSAN PRESENT QRYPTA EFFECTIVNESS AT THE AMERICAN HEADACHE AS

Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the...read more

zsan presentation at AMecian heache society july 13th

Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting July 01, 2019 16:05 ET | Source: Zosano Pharma Corporation FREMONT, Calif., July 01, 2019...read more

ZOSANO PREPARES FOR NDA SUBMISSION OF QTRYPTA DRUG

Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™ Technical Transfer of manufacturing process to CMO signals...read more

ZSAN SUMMARY OF POTENTIAL TIMELINE & CLINICAL RESULTS

Zosano: From Phase 3 To Approval Of A Best-In-Class Migraine Treatment https://seekingalpha.com/article/4265747-zosano-phase-3-approval-best-class-migraine-treatment May 22, 2019 9:40 AM ET Summary...read more

ZOSANO/ZSAN report earning results Q1 2019

Zosano Pharma Reports First Quarter 2019 Financial Results May 14, 2019 16:05 ET | Source: Zosano Pharma Corporation Multiple catalysts, including QtryptaTM NDA submission...read more

LongGuy, if you see this, what are you earning expectations?

thx eom  rate and reply

Earning announcement after MKT close tdy.

gl to all, i saw the announcement on this link  https://www.cnbc.com/quotes/?symbol=ZSAN  rate and reply

zsan/zosano positive migraine treatment study

Zosano up 5% premarket on favorable study of migraine treatments Apr. 16, 2019 9:14 AM ET |About: Zosano Pharma Corporation (ZSAN)|By: Douglas W. House, SA News Editor  ...read more

Update

Anyone have anything to share about this companies progress?  rate and reply

×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.